Please assess the completion status of the following clinical trial:

Trial Title: Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. born male, or born female and does not identify as female;~2. reports anal sex with men in the prior three months while under the influence of meth;~3. diagnosed with meth dependence by SCID;~4. interested in stopping or reducing meth use;~5. at least one meth-positive urine during screening and run-in period;~6. no current acute illness requiring prolonged medical care;~7. no serious chronic illnesses that are likely to progress clinically during trial participation;~8. able and willing to provide informed consent and adhere to visit schedule;~9. age 18-69 years;~10. baseline CBC, total protein, albumin, glucose, alkaline phosphatase, creatinine, BUN, and electrolytes without clinically significant abnormalities as determined by clinician in conjunction with symptoms, physical exam, and medical history~11. current CD4 count ≥ 200 cells/mm3; or CD4 count of 100 - 199 cells/mm3 and HIV viral load \< 200 copies/mL~12. text-capable cell phone or access to email~Exclusion Criteria:~1. Evidence of current major depression by SCID;~2. history of bipolar disorder or psychotic disorder, as determined by SCID;~3. known allergy or previous adverse reaction to mirtazapine;~4. taking an anti-depressant medication within the past 30 days, including mirtazapine or a monoamineoxidase inhibitor;~5. moderate or severe liver disease (AST, ALT, and total bilirubin \>= 5 times upper limit of normal);~6. impaired renal function (estimated GFR \<40 ml/min);~7. currently participating in another research study;~8. pending legal proceedings with high risk for incarceration during the time of planned study participation;~9. any condition that, in the principal investigator's judgment, interferes with safe study participation or adherence to study procedures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Mirtazapine (Type: ACTIVE_COMPARATOR): mirtazapine 30 mg orally per day
- Placebo (Type: PLACEBO_COMPARATOR): placebo (30 mg) orally per day

Based on this trial design, predict the completion outcome and termination type (if applicable).